Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23388043 | 0.88 | NPC1 (0.42) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL29749517 | 0.88 | NPC1 (0.42) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL3889222 | 0.82 | KDM4C (0.46) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL19715695 | 0.81 | KDM4C (0.35) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL30486438 | 0.79 | KDM4C (0.43) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL25228564 | 0.79 | KDM4C (0.43) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL17878832 | 0.78 | KDM4C (0.43) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL7737544 | 0.76 | KDM4C (0.43) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL19715819 | 0.76 | KDM4C (0.32) | KDM4CL3MBTL1NPC1RAB9A | |
| SCHEMBL29749639 | 0.76 | NPC1 (0.50) | KDM4CL3MBTL1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057815-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-20 | — | — | US | disclosed |
| US-20230390249-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-12-07 | — | — | US | disclosed |
| US-RE49352-E1 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220249443-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-08-11 | — | — | US | disclosed |
| CN-114601830-A | Carbamoyloxymethyltriazolylcyclohexanes as LPA antagonists | 百时美施贵宝公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-109963843-B | Carbamoyloxymethyltriazolylcyclohexanes as LPA antagonists | 百时美施贵宝公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3666771-B1 | LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3666771-B1 | LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210244711-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-11007180-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3666771-A1 | LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3666771-A1 | LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20200138789-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-07 | — | — | US | disclosed |
| EP-3472148-B1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10576062-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180333395-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | CHENG PETER TAI WAH (US) | 2018-11-22 | — | — | US | disclosed |
| US-10071078-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | KDM4C 2558/4885L3MBTL1 3287/4885NPC1 463/4885 |
| US-20220249443-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | KDM4C 2558/4885L3MBTL1 3287/4885NPC1 463/4885 |
| US-20210244711-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | KDM4C 2558/4885L3MBTL1 3287/4885NPC1 463/4885 |
| US-20200138789-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | KDM4C 2558/4885L3MBTL1 3287/4885NPC1 463/4885 |
| US-11007180-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | KDM4C 2558/4885L3MBTL1 3287/4885NPC1 463/4885 |
| US-20230390249-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | KDM4C 2558/4885L3MBTL1 3287/4885NPC1 463/4885 |
| US-10576062-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | KDM4C 2558/4885L3MBTL1 3287/4885NPC1 463/4885 |
| US-20250057815-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | KDM4C 2558/4885L3MBTL1 3287/4885NPC1 463/4885 |
| US-20180333395-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | KDM4C 2558/4885L3MBTL1 3287/4885NPC1 463/4885 |
| US-10071078-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | KDM4C 2558/4885L3MBTL1 3287/4885NPC1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.